RVMD News and Press, Revolution Medicines Inc. From 10/23/23

2023-10-23 08:31:36 ET Losers: Revolution Medicines ( RVMD ) -31% . Troika Media Group ( TRKA ) -21% . Li-Cycle Holdings Corp ( LICY ) -21% announces review of the rochester hub project . Mmtec ( MTC ) -18% . Palatin Technologies ( ...

REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced promising anti-tumor and safety data for RMC-6236, its RAS MULTI (ON) Inhibitor, in pati...

2023-10-19 14:23:20 ET More on Revolution Medicines Revolution Medicines: A Big Pipeline In Need Of Big Data Revolution Medicines' Strategic Edge In RAS-Driven Oncology Revolution Medicines, Inc. (RVMD) Q2 2023 Earnings Call Transcript Why did Revolution Medi...

2023-10-17 14:18:15 ET Are you looking for the best penny stocks to buy now ? Today might be your day…or not. These high-flying, low-priced stocks are well known for their innate ability to explode within a matter of minutes at times. Imagine seeing a stock that trades for pe...

2023-10-16 15:55:39 ET More on Revolution Medicines Revolution Medicines: A Big Pipeline In Need Of Big Data Revolution Medicines' Strategic Edge In RAS-Driven Oncology Revolution Medicines, Inc. (RVMD) Q2 2023 Earnings Call Transcript Revolution Medicines st...

2023-10-13 15:00:54 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

2023-10-13 14:54:35 ET Shares of Revolution Medicines (NASDAQ: RVMD) were up more than 20% as of 2 p.m. ET after the company announced positive phase 1/1b trial data for two cancer therapies. The clinical-stage biotech's stock is up more than 22% so far this year. Revolution...

2023-10-13 14:01:47 ET More on Revolution Medicines Revolution Medicines: A Big Pipeline In Need Of Big Data Revolution Medicines' Strategic Edge In RAS-Driven Oncology Revolution Medicines, Inc. (RVMD) Q2 2023 Earnings Call Transcript Revolution Medicines wi...

Clinical dose escalation data for RMC-6236, a RAS MULTI (ON) Inhibitor, show oral bioavailability, well-tolerated safety profile and preliminary evidence of anti-tumor activity across multiple RAS mutations First clinical data presentation for RMC-6291, a RAS G12C ...

Interim Data to be Presented for RMC-6236 (RAS MULTI (ON) Inhibitor) and RMC-6291 (RAS G12C (ON) Inhibitor) Company to Host Investor Webcast Following ESMO Data Presentation on October 22 at 12:30 p.m. Eastern REDWOOD CITY, Calif., Oct. 04, 2023 (GLOBE ...